Market Place
Sourcing Support
Sage discontinues Zulresso, drops pair of pipeline prospects
30 Oct 2024 //
FIERCE PHARMA
Sage Therapeutics Reveals Q3 2024 Financial Results and Pipeline
29 Oct 2024 //
BUSINESSWIRE
Zuranolone to face challenges in Japan’s MDD market
21 Oct 2024 //
EXPRESSPHARMA
Sage Therapeutics Ends Biogen Collaboration On SAGE-324
26 Sep 2024 //
BUSINESSWIRE
Sage Therapeutics Reports Q2 2024 Results And Pipeline Updates
31 Jul 2024 //
BUSINESSWIRE
FDA Approves Oral Treatment for Postpartum Depression
08 May 2024 //
DRUGTOPICS
Sage `highly encouraged` by Zurzuvae launch with Biogen
14 Feb 2024 //
FIERCE PHARMA
ZURZUVAE a Landmark Oral Treatment for PPD, is Now Available in the U.S.
14 Dec 2023 //
GLOBENEWSWIRE
Sage, Biogen call an audible on pricing strategy for Zurzuvae
07 Nov 2023 //
FIERCE PHARMA
FDA documents hint ‘uphill battle’ for broad approval of Sage’s depression drug
02 Sep 2023 //
BIOPHARMADIVE
Sage shrinks workforce by 40% in light of major depression drug rejection
01 Sep 2023 //
ENDPTS
Sage considers cuts after FDA’s split decision on depression drug
08 Aug 2023 //
BIOPHARMADIVE
US FDA approves Biogen-Sage Therapeutics pill for postpartum depression
05 Aug 2023 //
REUTERS
Novel investigational postpartum depression pill showed improvement in depressive symptoms
26 Jul 2023 //
BUSINESSWIRE
FDA says no adcomm planned for Biogen, Sage`s depression drug
09 Mar 2023 //
ENDPTS
Sage Therapeutics & Biogen Share Update on FDA Advisory Committee for Zuranolone
08 Mar 2023 //
BUSINESSWIRE
Eliem axes depression drug, lays off 55% of team to stretch cash
11 Feb 2023 //
FIERCE BIOTECH
Biogen and Sage Announce FDA Grants Priority Review of Zuranolone
06 Feb 2023 //
PRESS RELEASE
JPM23: Sage CEO says postpartum depression is no niche market
10 Jan 2023 //
FIERCEBIOTECH
Biogen and Sage Therapeutics Complete Rolling Submission of NDA for Zuranolone
06 Dec 2022 //
PRESS RELEASE
Sage and Biogen tout more data in hopes of alleviating durability concerns
20 Sep 2022 //
ENDPTS
Sage, Biogen`s drug meets main goal in postpartum depression study
02 Jun 2022 //
REUTERS
Sage, Biogen get rolling on FDA submission for depression med
03 May 2022 //
FIERCEBIOTECH
Sage scores on depression trial, but durability unanswered; shares sink
17 Feb 2022 //
YAHOO NEWS
Sage, Biogen Announce Positive, One-Year Zuranolone Data in MDD
01 Dec 2021 //
BUSINESSWIRE
AbbVie’s Vraylar turns in mixed results in depression
30 Oct 2021 //
FIERCEPHARMA
Biogen, Sage plot 2022 filing for zuranolone approval
20 Oct 2021 //
BUSINESSWIRE
Investigational Pill for Postpartum Depression Shows Promise in Clinical Trial
30 Jun 2021 //
BUSINESSWIRE
Biogen stocks up on Sage`s brain drugs in $3B deal
01 Dec 2020 //
BIOPHARMADIVE
Sage shares data on retreatment with depression drug zuranolone
16 Oct 2020 //
FIERCE BIOTECH
Sage to lay off half of workforce in cost-cutting retrenchment
09 Apr 2020 //
BIOPHARMADIVE
Sage to lay off half of workforce in cost-cutting retrenchment
07 Apr 2020 //
BIOPHARMADIVE
Sage to run 3 new studies to save once-failed depression drug
18 Mar 2020 //
FIERCE BIOTECH
Sage confirms suspension of 2 depression trials after PhIII flop
28 Feb 2020 //
ENDPTS
The winners and losers from JPM 2019
11 Jan 2019 //
BIOPHARMA DIVE
Sage shrugs off competition in postpartum depression plan to remain independent
07 Jan 2019 //
ENDPTS
Sage shares soar after oral postpartum depression treatment succeeds in trial
07 Jan 2019 //
REUTERS
Sage’s postpartum depression drug ticks efficacy, easing fears of fainting risk
07 Jan 2019 //
ENDPTS
Sage appears set for a breakthrough FDA OK on postpartum depression drug
05 Nov 2018 //
ENDPTS
Sage Therapeutics, Shionogi ink deal for MDD treatment
18 Jun 2018 //
BIOSPECTRUM
On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217
14 Jun 2018 //
ENDPTS
With a big assist from FDA, Sage plots a swift march PhIII oral depression drug
12 Jun 2018 //
ENDPTS
Sage shares surge 15% after FDA OKs expedited depression drug development
12 Jun 2018 //
CNBC
Does Sage`s Antidepressant Franchise Make It An Acquisition Target?
15 Jan 2018 //
SEEKINGALPHA
Sage Therapeutics Looks to File NDA for Postpartum Depression Treatment
12 Jan 2018 //
BIOSPACE
Likely FDA approval for postpartum depression drug pushes Sage therap stock 40%
10 Nov 2017 //
CNBC
Sage soars on small postpartum depression study results
12 Jul 2016 //
FIERCE BIOTECH
